Tumor Lysis Syndrome

Tumor Lysis Syndrome (TLS) refers to the metabolic consequences of the break-up of a tumor within the body, generally on account of cytotoxic (i.e. chemotherapeutic) intervention. In other words, when a cancer patient receives treatment, the cancer cells that are killed release their contents into the bloodstream and throw the metabolic state of the blood out of balance. This is characterized by three serious conditions:

Hyperkalemia: This is a build-up of potassium in the blood, or higher-than-normal levels of potassium in the blood.

Hyperphosphatemia: This is a build-up of phosphates in the blood.

Hyperuricemia: This is a build-up of uric acid in the blood

In all cases, it is the role of the kidneys to clear these substances from the blood, which is why kidney failure is a very real concern when coping with TLS.

Risk Factors for TLS

The highest degree of risk for TLS derives from those tumors that are known to grow the fastest, chiefly because they are known to be most susceptible to chemotherapy and similar anti-cancer interventions. These tumors include:

-- Lymphoblastic Lymphoma
-- Burkitt's lymphoma
-- T-cell acute lymphoblastic leukemia

Lower risk tumors include:
-- Low grade lymphomas
-- Small cell carcinomas
-- Breast carcinomas
-- Multiple myelomas

Other risk factors include:

-- Bulky disease
-- Hepatosplenomegaly (the swelling of the liver and the spleen beyond normal size)
-- High leukocyte count
-- Elevated LDH levels (pre-treatment)
-- Elevated levels of uric acid (pre-treatment)
-- Compromised kidney functions
-- Decreased urine output

Treatment strategies

There are several treatment strategies for Tumor Lysis Syndrome, and the subject is far too extensive for the scope of this entry. However, patients should be made aware by their physicians if they are at higher risk of developing TLS following anti-cancer treatment, and if so, what prophylactic measures can be taken to prevent the syndrome from developing in the first place.

Sources

Boyiadzis, Michael M. et al. Hematology-Oncology Therapy. 2007. New York: McGraw Hill, Medical Publishing Division.
PubMed Health: Hyperkalemia
MedlinePlus: Hepatomegaly

More Articles

More Articles

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...

Secondary cancers are cancers that develop as a result of chemotherapy and/or...

One of the greatest fears of lymphoma survivors is that they’ll relapse and have to undergo treatment again. This fear is normal but awful to...

Over the years, various classification systems have been used to differentiate lymphoma types including the Rappaport Classification (used until...

If you are new to this website or are looking for guidance to a specific page, here is a list of links to articles that can help you. The "Main...

Often the one who makes the first diagnosis of Hodgkin's Lymphoma / Disease is the person affected. There are some...

Lymphedema is abnormal swelling due to the presence of excess lymphatic fluid within the tissues. This swelling occurs when the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Advances in the treatment of Hodgkin's lymphoma have resulted in remarkable survival rates, even for...